![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Hvivo Plc | LSE:HVO | London | Ordinary Share | GB00B9275X97 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.75 | 2.75% | 28.00 | 27.60 | 28.00 | 27.80 | 27.25 | 27.25 | 2,193,935 | 16:35:24 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 56.04M | 16.12M | 0.0237 | 11.73 | 185.4M |
TIDMVENN
RNS Number : 7350I
Venn Life Sciences Holdings PLC
11 December 2015
Pre-Admission Announcement
ESM Schedule 1
Announcement to be made by the ESM Applicant prior to admission in accordance with rule 2 of the ESM Rules for Companies ------------------------------------------------------------------------ All Applicants must complete the following Company name Venn Life Sciences Holdings plc ("Venn Life Sciences" or the "Company") Company registered address and if different, company trading address (including postcodes) Registered Office: 1 Berkeley Street, London, WIJ8DJ, UK ------------------------------------------------------------------------ Country of incorporation England and Wales ------------------------------------------------------------------ ---- Company website address containing all information required by rule 26 in the ESM Rules for Companies http://www.vennlifesciences.com/investor-aim-rules/ ------------------------------------------------------------------------ Company business (including main country of operation) or, in the case of an investing company, details of its investing strategy. If the admission is sought as a result of a reverse takeover under rule 14 of the ESM Rules for Companies, this should be stated Venn Life Sciences is a European Contract Research Organisation providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK, Ireland and Europe wide representation - Venn offers clients a full spectrum of services form non-clinical through all clinical phases. Venn also has an innovation division - Innovenn - focused primarily on breakthrough development opportunities in Skin Science. Venn's current capabilities have developed through a combination of acquisitions and organic growth. Venn expects to continue to develop in this way and intends broadening it's footprint further in Europe. Venn Life Sciences is headquartered in Dublin, Ireland and has subsidiaries operating in France, Germany, the Netherlands and the UK (together the "Group"). ------------------------------------------------------------------------ Details of securities to be admitted including any restrictions as to transfer of securities (i.e. where known, number of shares, nominal value and issue price to which it seeks admission and the number and type to be held as treasury shares) The total number of ordinary shares of GBP0.001 each ("Ordinary Shares") to be admitted to ESM is 60,239,263. The price of each Ordinary Share to be admitted to ESM is likely to reflect the prevailing share price on AIM adjusted for the prevailing EUR:GBP exchange rate. Except as provided for by the lock-up agreement with Mr Kees Groen an Executive Director of the Company who is beneficially interested in 4,780,320 Ordinary Shares (amounting to 7.9% of the issued share capital of the Company) which are subject to a lock up period of 12 months from 16 October 2015, there are no restrictions on the transfer of securities to be admitted. Mr Groen received these Ordinary Shares as part consideration following the sale of his company, Kinesis, to Venn Life Sciences in October 2015. ------------------------------------------------------------------------ Capital to be raised on admission (if applicable) and anticipated market capitalisation on admission No capital to be raised on admission to ESM The anticipated market capitalisation of Venn Life Sciences on admission is expected to be EUR16 million. --------------------------------------------------------------------------- Percentage of ESM securities not in public hands on admission Approximately 89% --------------------------------------------------------------------------- Details of any other exchange or trading platform to which the ex securities (or other securities of the company) are or will be admitted or traded The Ordinary Shares were admitted to trading on the AIM market of the London Stock Exchange on 14 December 2012 --------------------------------------------------------------------------- Full names and functions of directors and proposed directors (underlining the first name by which each is known or including any other name by which each is known) Mr David Evans (Non-Executive Chairman) Mr Tony Richardson (Chief Executive Officer) Mr Jonathan Hartshorn (Chief Financial Officer) Mr Michael Ryan (Non-Executive Director) Mr Paul Kennedy (Non-Executive Director) Ms Gracielle Anna Maria Beijerbacht-Schutjens (Executive Director) Mr Kees Groen (Executive Director) --------------------------------------------------------------------------- Full names and holdings of significant shareholders, expressed as a percentage of the issued ordinary share capital, before or after admission (underlining the first name by which each is known or including any other name by which each is known) Name No. of ordinary % of existing shares share capital ------------------ ---------------- --------------- Livingbridge VC LLP 5,263,157 8.7% ------------------ ---------------- --------------- Calculus Capital Limited 5,106,117 8.5% ------------------ ---------------- --------------- Kees Groen 4,780,320 7.9% ------------------ ---------------- --------------- David Newton 2,200,000 3.7% ------------------ ---------------- --------------- ------------------------------------------------------------------------------ Names of all persons to be disclosed in accordance with schedule two, paragraph (h) of the ESM Rules for Companies N/A ------------------------------------------------------------------------------ i anticipated accounting reference date 31 December ii date to which the main financial information in the admission document has been prepared N/A admission to ESM via Designated Markets Route iii dates by which it must publish its first three reports pursuant to Rules 18 and 19 in the ESM Rules for Companies a. Year ended 31 December 2015 by 29 April 2016; b. 6 months ended 30 June 2016 by 30 September 2016; and c. Year ended 31 December 2016 by 28 April 2015. ------------------------------------------------------------------------- --- Expected admission 18 January 2016 ----------------------------------------------------------------------- ----- Name and address of ESM Adviser Davy Corporate Finance Davy House 49 Dawson Street Dublin 2 Ireland Name and address of broker(s) Davy Davy House 49 Dawson Street Dublin 2 Ireland Hybridan LLP 20 Ironmonger Lane London EC2V 8EP ------------------------------------------------------------------------------ Other than in the case of a quoted Applicant, details of where (postal or internet address) the admission document will be available from, with a statement that this will contain full details about the Applicant and the admission of its securities ------------------------------------------------------------------------------ N/A ------------------------------------------------------------------------------ Date of notification 11 December 2015 ----------------------------------------------------------------------- ----- New/update (see note): New ----------------------------------------------------------------------- ----- Quoted Applicants must also complete the following The name of the ESM designated market upon which the Applicant's securities have been traded AIM ------------------------------------------------------------------------------------ The date from which the Applicant's securities have been so traded 14 December 2012 ------------------------------------------------------------------------------------ Confirmation that, following due and careful enquiry, the Applicant has adhered to any legal and regulatory requirements involved in having its securities traded upon such a market or details of where there has been any breach The Company has adhered to the legal and regulatory requirements applicable to companies admitted to trading on the AIM market of the London Stock Exchange plc. ------------------------------------------------------------------------------------ An address or web-site address where any documents or announcements which the Applicant has made public over the last two years (in consequence of having its securities so traded) are available http://www.vennlifesciences.com/shareholder-information/regulatory-news-service-rns/ ------------------------------------------------------------------------------------ Details of the Applicant's strategy following admission including, in the case of an investing company, details of its investment strategy Venn Life Sciences is a European Contract Research Organisation providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK, Ireland and Europe wide representation - Venn offers clients a full spectrum of services form non-clinical through all clinical phases. Venn also has an innovation division - Innovenn - focused primarily on breakthrough development opportunities in Skin Science.
(MORE TO FOLLOW) Dow Jones Newswires
December 11, 2015 02:00 ET (07:00 GMT)
1 Year Hvivo Chart |
1 Month Hvivo Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions